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should be the targets of therapeutic intervention. Some
of the more notorious critics of mouse tumor models
might start thinking about lowering their collective
voices.
Anton Berns
Division of Molecular Genetics and Centre
of Biomedical Genetics
The Netherlands Cancer Institute
1066 CX Amsterdam
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RNA Interference Libraries
Prove Their Worth in Hunt for
Tumor Suppressor Genes
RNA interference has been promoted as an ideal tool
for functional genomics, but to date the success sto-
ries have principally been in model organisms. Two
papers in this issue of Cell change all that: Westbrook
et al. (2005) and Kolfschoten et al. (2005) use RNA
interference libraries targeting large proportions of
the human genome to uncover two novel tumor sup-
pressor genes. REST is a transcriptional repressor
that silences neuron-specific gene expression, and
PITX1 is a homeodomain transcription factor that pro-
motes the expression of a negative regulator of Ras.The use of RNA interference libraries targeting whole
genomes has become a standard tool for the investiga-
tion of biological processes in worms and flies, but to
date this methodology has not achieved any notable
advances in mammalian systems, although some suc-
cesses have been achieved with smaller, more focused
collections (Downward, 2004). Two large retroviral li-
braries of RNA interference vectors targeting 8000–9000
human genes were reported about a year ago (Berns et
al., 2004; Paddison et al., 2004), and it is these that
have now been used in two independent studies to
search for novel tumor suppressor genes. The interest-
ing nature of the two genes identified, REST and PITX1,
demonstrates the power of this approach.
Both studies start from the premise that immortalized
human cells that are one step short of transformation
would make excellent systems in which to find tumor
suppressor genes using large collections of RNA inter-
ference vectors. Inactivation of a single tumor suppres-
sor gene may be sufficient to tip the cells over the edge
into a frankly transformed phenotype that can be se-
lected for. Westbrook et al. (2005) use human mammary
epithelial cells that have been immortalized by the ex-
pression of telomerase and SV40 large T antigen and
also naturally express high levels of Myc. Kolfschoten
et al. (2005) use human BJ fibroblasts expressing
telomerase, SV40 small t antigen, and RNA interference
vectors targeting p53 and p16. Both these cell lines are
entirely dependent on anchorage to extracellular matrix
for their survival and proliferation and can thus be con-
sidered “normal” but can be transformed by just the
expression of activated Ras or knockdown of PTEN,
leading to anchorage-independent growth.
In both studies, large pools of RNA interference vec-
tors were introduced into the cells by retroviral infec-
tion, and the small numbers of anchorage-independent
clones emerging were selected. The RNAi vectors caus-
ing the transformed phenotype were directly sequenced
from these cell clones. In addition, Westbrook et al.
(2005) also used a second approach to identify the
genes knocked down: “barcode” screening (Brummel-
kamp and Bernards, 2003). In the library of Paddison et
al. (2004), additional unique barcode sequences have
been added to the vectors, which can be identified
using microarrays containing oligonucleotides corre-
sponding to the barcode sequences. The barcode sys-
tem has tremendous potential for identifying biolo-
gically active RNAi vectors in situations in which a
strong positive selection is not possible; although this
was not the case here, this study does represent its
first successful use to find novel genes and suggests that
barcodes may be successful in less optimal screens.
Westbrook et al. (2005) identified a significant num-
ber of potential tumor suppressor genes in this way, of
which they confirmed five by demonstrating that two
independent RNAi sequences targeting them would
cause anchorage-independent growth, including the
well-known tumor suppressor gene TGFBR2, which en-
codes the type II receptor for TGF-β. It is clearly pos-
sible that this screen might identify genes that can act
to limit anchorage-independent growth in this particular
artificial cell system but which may never contribute to
human tumorigenesis. However, array-based compara-
tive genomic hybridization was used to show that two
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814of these genes, TGFBR2 and REST, are deleted at a i
isignificant frequency in human tumors. Evidence of de-
letions in the region of chromosome 4 where REST is c
flocated were found in about a third of human tumors
examined, although many other genes share this loca- b
Ttion. Microdeletions affecting REST were found in two
colon cancers, plus evidence of a point mutation result- t
ling in a dominant-negative form of REST in the well-
studied colon cancer cell line DLD-1, which also bears c
oan activating KRAS mutation. While this evidence cer-
tainly falls short of proof that REST is a significant hu- A
eman tumor suppressor gene, it definitely makes it a
very good candidate for further investigation. c
oREST encodes a transcriptional repressor that si-
lences the expression of neuronal-specific genes, in- t
Gcluding neurotrophins, in nonneuronal tissues (Chong
et al., 1995). A plausible explanation for its role as a e
ttumor suppressor could be that its deletion allows ex-
pression of genes involved in promoting neuronal prolif- c
teration in epithelial tissues. While the exact mechanism
here remains to be determined, loss of REST can result t
in inappropriate expression of neurotrophins, such as
BDNF, or their receptors, such as TrkC, which could p
cdrive transformation via activation of phosphatidylino-
sitol 3-kinase (PI 3-kinase) and other Ras-dependent c
cpathways (see Figure 1A). Recently, a gain-of-function
screen for proteins able to promote anchorage-inde- f
bpendent growth in epithelial cells identified TrkB, so
clearly inappropriate activation of neurotrophic path- m
rways in nonneuronal cells can lead to malignancy
(Douma et al., 2004). Indeed, there is evidence that ex- t
wpression of neuronal markers frequently occurs in some
epithelial tumor types: very occasionally this can lead v
ito an autoimmune response targeting nervous tissue,
a rare malignancy-associated disorder termed para- u
oneoplastic neurological degeneration (Albert and Dar-
nell, 2004). p
mKolfschoten et al. (2005) identified a number of genesFigure 1. Models for the mechanism of the
tumor suppressive function of REST (A) and
PITX1 (B). See text for details.n their screen, a couple of which had previously been
mplicated as possible tumor suppressors. They con-
entrated, however, on the homeodomain transcription
actor PITX1. Knockdown of this gene allows fibro-
lasts to grow in an anchorage-independent manner.
he mechanism appears to involve constitutive activa-
ion of the Ras signaling pathways at the level of GTP
oading onto Ras itself, suggesting that PITX1 might
ontrol the expression of one of the negative regulators
f Ras of the GTPase-activating protein (GAP) family.
n analysis of the sequences of the promoters of the
ight human genes encoding Ras GAPs led them to
oncentrate on RASAL1, a calcium-sensitive member
f the family (Walker et al., 2004). PITX1 directly con-
rols the expression of RASAL1, with the reduction in
AP activity when PITX1 and consequently RASAL1
xpression is lost being sufficient to induce the activa-
ion of endogenous wild-type Ras proteins within the
ell (see Figure 1B). Loss of PITX1 thus has the poten-
ial to have a similar effect to mutation of RAS genes in
erms of activation of downstream Ras effector pathways.
How good is the evidence that PITX1 is a tumor sup-
ressor gene in human cancer? There is certainly pre-
edent for the disregulation of Ras GAPs in human can-
er from type I neurofibromatosis, an inherited disorder
haracterized by high tumor incidence caused by de-
ects in the NF1 gene encoding the Ras GAP neurofi-
romin. While there is not yet evidence that PITX1 is
utated or deleted in human tumors, its expression is
educed in many prostate and bladder cancers relative
o their normal tissue. Interestingly, in colon cancer, in
hich KRASmutation rates are are about 40%, the acti-
ation state of Ras (the ratio of bound GTP to GDP)
n cell lines lacking such mutations was shown to be
nexpectedly elevated, suggesting possible disruption
f negative regulation of Ras in these cells. It is re-
orted that there is a strong correlation between the
utation of KRAS and PITX1 expression, with colon tu-
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815mors with wild-type Ras showing very low levels of
PITX1. The strong implication is that, in these tumors,
endogenous wild-type Ras proteins are activated due
to reduced levels of the negative regulator RASAL1
downstream of suppression of PITX1 expression. The
evidence that PITX1 is a significant tumor suppressor
gene in human cancer remains largely circumstantial but
is clearly worth further study.
These two studies highlight the power of selective
screens using vector-based RNA interference libraries
to uncover important novel players in human cancer.
Two important mechanisms of carcinogenesis are high-
lighted: loss of suppression of neurotrophic genes in
nonneuronal tissue and loss of expression of negative
regulators of Ras. The prospects for gaining many more
insights into the process of carcinogenesis using these
technologies now look bright.
Julian Downward
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